secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041601
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q2 net loss $15.9M; cash $144.1M; Apexigen deal on track for August close
--------------------------------------------------------------------------------

- Net loss $15.9M ($0.41/share) vs $25.6M ($0.79) in Q2 2022; loss narrowed on lower R&D and G&A.
- Cash and short-term investments $144.1M as of June 30, 2023; expected runway into first half of 2025.
- R&D expenses $11.4M (down from $17.2M YoY); G&A $6.7M (down from $8.6M YoY).
- Third dose cohort initiated in Phase 1 trial of ADC PYX-201; three European sites recruiting.
- Apexigen acquisition expected to close later in August 2023; sotigalimab development plan in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/0000950170-23-041601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/pyxs-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer